Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations is a phase 3 interventional study registered as NCT04687241 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 192 participants planned, started 2021-04-30 and due to reach its primary completion in 2024-07-08. Interventions recorded: Almonertinib, Placebo Almonertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAENEAS
Shares Aumolertinib, Non-small-cell lung cancer.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Aumolertinib, Non-small-cell lung cancer.